Trials / Recruiting
RecruitingNCT06994338
Tirzepatide for Alcohol Use Disorder
Phase II Evaluation of Tirzepatide in Adults With Alcohol Use Disorder and Overweight or Obesity
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- University of Southern California · Academic / Other
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Tirzepatide injections (2.5mg, 5.0mg) |
| DRUG | Placebo injections | Placebo injections |
Timeline
- Start date
- 2025-10-06
- Primary completion
- 2026-08-31
- Completion
- 2026-08-31
- First posted
- 2025-05-29
- Last updated
- 2025-10-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06994338. Inclusion in this directory is not an endorsement.